Leader in Next-Generation Sequencing Advances Innovation in Healthcare with Capital and Appointment of New Board Member
SAN CARLOS, Calif., Jan. 13, 2025 /PRNewswire-PRWeb/ -- Today, Clear Labs, provider of fully automated, next-generation sequencing (NGS) platforms for turnkey diagnostics, announced it has secured $30 million in its Series D financing. The round was led by a strategic investor, along with participation from existing investors, including Counterpoint Global (Morgan Stanley), Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, and funds and accounts advised by T. Rowe Price Associates, Inc.
Following its strong growth trajectory, including new innovative assays and enhancements to the Clear Dx™ platform, the funding enables Clear Labs to continue accelerating the development and adoption of its cutting-edge NGS solutions while scaling operations to meet the demand for fully automated turnkey genomics solutions worldwide.
"This is an important moment for Clear Labs - the continued investment from industry leaders who understand and support our mission validates the promise of our NGS technology to simplify and streamline sequencing workflows, redefine NGS-based workflows, and improve healthcare outcomes," said Dr. Sasan Amini, PhD, co-founder and CEO of Clear Labs. "We have proven our approach, and this financing allows us to expand our solution to new customers and markets and ultimately, aims to improve the way labs approach NGS testing."
Clear Labs' turnkey NGS platform accelerates outcomes and improves accuracy by fully automating the entire sequencing workflow, including the process of translating DNA sequencing data into genomic insights. The company has a significant presence in the U.S. and is expanding internationally into new regions, including Europe and Latin America.
"Clear Labs is revolutionizing the NGS industry by providing a seamless platform that combines robotics, bioinformatics, and DNA sequencing," said Greg Yap, Partner at Menlo Ventures. "Their technology sets a new standard for speed, efficiency, and simplicity for NGS testing while reducing costs and making high-quality diagnostics accessible to more institutions. We're proud to continue supporting Sasan and the Clear Labs team because we know they are delivering the clarity needed to help inform healthcare decisions and protect lives."
With this news, Clear Labs is adding Kevin Keegan, Becton Dickinson's Vice President and Global Platform Leader, Molecular Diagnostics, to its Board of Directors. Keegan was previously Illumina's Vice President and General Manager of Oncology.
"Clear Labs is leading the charge in making complex genomics accessible, accurate, and impactful for healthcare institutions, and I'm eager to contribute to scaling their innovative approach to deliver accurate and near real-time results," added Keegan.
"Kevin adds to our impressive pedigree of talented team members, and his industry insights and operational expertise will help Clear Labs continue to evolve to meet new needs. We're glad that he has joined us for this next important chapter of the Clear Labs story," added Dr. Amini.
As the pioneer in turnkey genomic applications, Clear Labs has democratized NGS for infectious diseases. The Series D financing allows the company to expand to additional markets while supporting its mission to liberate genomics to all and advance healthcare through innovation. For more information, visit https://www.clearlabs.com/.
About Clear Labs
Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for the clinical and applied markets. By providing a fully-automated, turnkey NGS platform that integrates DNA sequencing, robotics, and cloud-based bioinformatics and analytics, Clear Labs empowers healthcare institutions with everything they need to perform advanced genomics in-house in their own labs. With Clear Labs, health systems can now accelerate healthcare outcomes, enhance accuracy and improve lab efficiencies while reducing costs.
Media Contact
Aimee Eichelberger, 983 Group, (312) 952-1528, [email protected]
SOURCE Clear Labs
Share this article